Cycle Pharmaceuticals announced that it has signed an agreement with Catalent on the Zydis oral disintegrating tablet (ODT) and Zydis Ultra technologies.
Under the agreement, Cycle will manufacture four of its products treating rare metabolic and neurological disorders using the Zydis technology, which, according to Cycle, offers ‘well-established’ advantages over conventional oral dosage forms, including improved patient compliance, adherence and convenience.
Antonio Benedetti, CEO of Cycle, commented that Catalent’s platform was also chosen due to its “effectiveness in overcoming challenges faced by patients, such as swallowing difficulties and large pill burdens.”
Zydis Ultra technology was commercialized earlier this year, with Catalent investing $27m (€24.22m) to put the formulation technology on the market.
According to the company, the ODT technology allows increased drug load and better taste masking than its predecessor, Zydis, which is a freeze-dried tablet that disperses almost instantly in the mouth without water.
More specifically, Zydis Ultra utilizes a patented drug coating to be introduced during a product’s formulation, enabling up to four times higher dosage of active ingredient than a conventional Zydis ODT, while maintaining its speed of dispersion.